• Explore /
  • Poster
  • / HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.

HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.

Abstract Video & Slides Poster

Authors

David Chism

David D. Chism

Thompson Cancer Survival Center, Knoxville, TN

David D. Chism , Biren Saraiya , Tanya B. Dorff , Brendan D. Curti , Edwin Melencio Posadas , Carlyle St. Paul , Subhendu Mukhopadhyay , Leena Desai , Henning Lauterbach , Rounak Nassirpour , Alexander Grill , Ali Manouchehri , Kia Katchar , Kevin Hibbert , Katia Schlienger , Susan F. Slovin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT05553639

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5108)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5108

Abstract #

TPS5108

Poster Bd #

197a

Abstract Disclosures

Similar Posters

First Author: Russell Kent Pachynski

First Author: Arpit Rao

First Author: Arpit Rao

First Author: Rana R. McKay